Clearmind Medicine Inc. (NASDAQ: CMND) announced that its drug candidate CMND-100 met the primary safety and tolerability endpoint in an FDA-approved Phase I/IIa clinical trial for alcohol use disorder treatment.

The Vancouver-based biotech company reported that results from the trial's third cohort showed a high safety profile for CMND-100, even at higher dosages. The drug candidate was well tolerated with no serious adverse events reported in the third cohort, according to the company's statement.

CMND-100 is described as a proprietary non-hallucinogenic MEAI-based oral drug candidate. The Phase I/IIa trial is a multinational, multicenter study designed to evaluate safety, tolerability, pharmacokinetics, and preliminary efficacy of the drug in patients with moderate to severe alcohol use disorder.

The trial follows a dose-escalation design, with the third cohort receiving the highest dosage administered to date. The company stated that meeting the primary endpoint supports continued development of CMND-100 as a potential treatment option for alcohol use disorder.

Clearmind Medicine focuses on developing what it calls neuroplastogen-derived therapeutics. The company holds an intellectual property portfolio of 19 patent families, including 31 granted patents.

The information comes from a company press release issued April 14, 2026.